Bioprocessing White Papers

31. Tailoring Viral Clearance Study Design 3/4/2026

    Viral‑clearance studies need phase‑appropriate design, strong virus stocks, modality‑specific risk assessment, and alignment with evolving regulations for reliable safety outcomes.

32. Key Selection Criteria For Cell & Gene Therapy CDMOs 3/4/2026

    Choosing the right CDMO requires early internal assessment plus strong technical capability, agility, advocacy, clear communication, and long‑term alignment to meet evolving cell and gene therapy needs.

33. Alleviate Compliance Risks With Your EAM/CMMS 3/2/2026

    Discover how unified asset management enhances audit readiness by connecting maintenance, calibration, and quality insights, as well as how integrated workflows reduce compliance risk.

34. A Journey To Produce MSC-Derived Cell Therapies From Isolation To Large-Scale 2/26/2026

    Drive successful MSC therapy development by optimizing isolation methods, surface chemistry, and closed-system expansion technologies to ensure cellular stability and commercial scalability.

35. Soil Testing: From Filtration To Fertilizer To Food 2/25/2026

    Soil analysis offers a clear view of the factors that influence land productivity while helping identify contaminants that could threaten safety. Understand the indicators to support sustainability decisions.

36. A Comprehensive Solution For Adventitious Agent Testing 2/13/2026

    Modern sequencing methods offer sensitive detection of adventitious and species‑specific viruses. Learn how targeted and non‑targeted NGS approaches improve confidence in cell bank characterization.

37. Collaborative Variability Reduction In Cell Culture Media 2/13/2026

    Variability reduction programs improve biomanufacturing by controlling raw‑material complexity, optimizing critical attributes, and boosting productivity through data‑driven partnerships.

38. Using Plant Peptones To Boost Plasmid Yield And Induction 2/12/2026

    Uncover how Nu‑Tek’s plant-based peptones support E. coli growth, plasmid yield, and controlled induction, offering a sustainable, animal-free alternative for biopharmaceutical cell culture.

39. FIH: Reach Milestones Sooner With A Technology-Driven Approach 2/12/2026

    Accelerate your path to IND and FiH with AI-driven design, advanced cell line engineering, and intensified processes delivering high titers in 9–14 months.

40. Digital Solutions Enhance Pharmaceutical Manufacturing Performance 2/6/2026

    Personalised therapies and advanced technologies are reshaping manufacturing. Explore how intelligent automation can improve flexibility, strengthen data integrity, and accelerate production.